Chemotherapy induced emesis: pathophysiology and prevention

被引:3
|
作者
Mailliez, A. [1 ]
Bonneterre, J. [1 ]
机构
[1] Ctr Oscar Lambret, Dept Senol, F-59000 Lille, France
关键词
anti-emetic therapy; 5-HT3 serotonin receptor antagonists; NK1 receptor antogonists; steroids; anti-emetic guidelines; CISPLATIN-INDUCED EMESIS; MODERATELY EMETOGENIC CHEMOTHERAPY; ORAL NEUROKININ-1 ANTAGONIST; 5-HT3 RECEPTOR ANTAGONIST; PLACEBO-CONTROLLED TRIAL; HIGH-DOSE METOCLOPRAMIDE; PHASE-II TRIAL; INDUCED NAUSEA; DOUBLE-BLIND; RANDOMIZED CROSSOVER;
D O I
10.1684/bdc.2009.0979
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Nausea and emesis are one of the most feared secondary effect of chemotherapy. The development of antiemetic therapies has increased after the introduction of cisplatin, a cytotoxin with the highest emetic potential. Chemotherapy-induced nausea and vomiting (CINV) have been classified into acute, delayed and anticipatory based on the time of onset. According to the percentage of nausea and emesis without any antiemetic treatment, chemotherapy is divised into highly, moderate, low and very low emetic potential. The discovery of emetics stimuli neurotransmitters and their receptors has led to the introduction of new molecules which associated with steroids have prevented nausea and vomiting chemotherapy-induced for 70 to 80% of the patients receiving chemotherapy with high emetic potential. Numerous studies have evaluated the various antiemetics and recommendations were issued by learned societies in US and Europe. This text discusses the physiopathology of nausea and vomiting, the development of anti-emetics and the new discovered antiemetics. Finally, a synthesis of the recommandations from the guidelines developed by the Multinational Association of Supportive Care in Cancer (MASCC), the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) is presented. triangle
引用
收藏
页码:233 / 243
页数:11
相关论文
共 50 条
  • [31] Prevention of radiotherapy-induced emesis
    Roila, F
    Ciccarese, G
    Palladino, MA
    De Angelis, V
    [J]. TUMORI, 1998, 84 (02) : 274 - 278
  • [32] PREVENTION OF CISPLATIN-INDUCED EMESIS
    ROILA, F
    TONATO, M
    BALLATORI, E
    DELFAVERO, A
    [J]. LANCET, 1992, 340 (8825): : 972 - 972
  • [33] Pathophysiology and prevention of cancer chemotherapy-induced bone growth defects
    Xian, C. J.
    Fan, C. M.
    Cool, J. C.
    Scherer, M. A.
    King, T.
    Georgiou, K.
    Nadhanan, R. Raghu
    Howarth, G. S.
    Shandala, T.
    Foster, B. K.
    [J]. BONE, 2009, 45 : S103 - S103
  • [34] Prevention of delayed emesis induced by moderately emetogenic chemotherapy in patients with acute emesis - A pilot study with ACTH-Depot plus tropisetron
    Santini, D
    Vincenzi, B
    Fossati, C
    D'Angelillo, RM
    Patti, G
    Bianco, V
    Avvisati, G
    Tonini, G
    [J]. MEDICAL ONCOLOGY, 2001, 18 (02) : 131 - 135
  • [35] Prevention of delayed emesis induced by moderately emetogenic chemotherapy in patients with acute emesis: A pilot study with ACTH-depot plus tropisetron
    Santini D.
    Vincenzi B.
    Fossati C.
    D'Angelillo R.M.
    Patti G.
    Bianco V.
    Avvisati G.
    Tonini G.
    [J]. Medical Oncology, 2001, 18 (2) : 131 - 135
  • [36] COMPARISON OF 2 DIFFERENT HIGH-DOSES OF METOCLOPRAMIDE IN THE PREVENTION OF CHEMOTHERAPY-INDUCED EMESIS
    VANGROENINGEN, CJ
    GALL, HE
    SIMONS, KA
    VANLOENEN, AC
    KNOBF, MK
    NAUTA, J
    VERMORKEN, JB
    PINEDO, HM
    [J]. NETHERLANDS JOURNAL OF MEDICINE, 1989, 35 (5-6): : 283 - 294
  • [37] Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis
    Lindley, C
    Blower, P
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2000, 57 (18) : 1685 - 1697
  • [38] Optimal combination therapy in the prevention of acute and delayed emesis induced by highly emetogenic chemotherapy (CT)
    Spaeth, D
    Conroy, T
    Bleuse, JP
    [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1249 - 1249
  • [39] Standard treatment of chemotherapy-induced emesis
    David Warr
    [J]. Supportive Care in Cancer, 1997, 5 : 12 - 16
  • [40] ARGININE VASOPRESSIN - A MEDIATOR OF CHEMOTHERAPY INDUCED EMESIS
    EDWARDS, CM
    CARMICHAEL, J
    BAYLIS, PH
    HARRIS, AL
    [J]. BRITISH JOURNAL OF CANCER, 1989, 59 (03) : 467 - 470